Remarkable Response to Chemo-immunotherapy In Anaplastic Thyroid Cancer

Anaplastic thyroid cancer (ATC) is an aggressive and lethal malignancy with limited therapeutic options and poor prognosis. In recent years, the therapeutic arsenal of locally advanced or metastatic ATC has been expanded, with V-Raf murine sarcoma viral oncogene homolog B (BRAF)/mitogen-activated protein kinase kinase-MAPKK (MEK) inhibitors for the subset of BRAF V600E-mutant ATC. For BRAF wild-type ATC and without other actionable alterations, the most promising strategy is certainly immune checkpoint inhibitors, which have shown activities both in monotherapy or in combination regimens. However, access to novel treatments is heterogeneous worldwide for ATC patients, and activity of immunotherapy as a single agent is limited. We report the case of a patient with locally advanced BRAF wild-type ATC who achieved a near-complete and durable response following a multimodal treatment approach combining chemotherapy (carboplatin and paclitaxel), immunotherapy (pembrolizumab), and external beam radiotherapy. Pembrolizumab monotherapy was continued as maintenance therapy, and disease control was maintained for over 1 year. This case highlights the potential efficacy of chemo-immunotherapy in BRAF wild-type ATC, especially when a rapid tumor reduction is required. It supports the use of immune checkpoint inhibitors combined with cytotoxic agents as a viable therapeutic option in this aggressive tumor subtype.